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SecretionUric acid transporter URAT1 contributes signiﬁcantly to reabsorption of uric acid in humans to maintain a
constant serum uric acid (SUA) level. Since alteration of SUA level is associated with various diseases, it is
important to clarify the mechanism of change in SUA. However, although expression of mRNA of an ortholog
of URAT1 (rUrat1) in rats has been reported, functional analysis and localization have not been done.
Therefore, rat rUrat1 was functionally analyzed using gene expression systems and isolated brush-border
membrane vesicles (BBMVs) prepared from rat kidney, and its localization in kidney was examined
immunohistochemically. Uric acid transport by rUrat1 was chloride (Cl−) susceptible with a Km of 1773 μM.
It was inhibited by benzbromarone and trans-stimulated by lactate and pyrazinecarboxylic acid (PZA). Cl−
gradient-susceptible uric acid transport by BBMVs showed similar characteristics to those of uric acid
transport by rUrat1. Moreover, rUrat1 was localized at the apical membrane in proximal tubular epithelial
cells in rat kidney. Accordingly, rUrat1 is considered to be involved in uric acid reabsorption in rats in the same
manner as URAT1 in humans. Therefore, rUrat1 may be a useful model to study issues related to the role of
human URAT1.+81 76 264 6284.
).
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Uric acid is the end product of purine metabolism in humans [1].
Serum uric acid (SUA) level is maintained by the balance between
synthesis, catalyzed by xanthine oxidoreductase, and excretion [2].
Uric acid is mainly produced in liver, muscles, and intestine.
Approximately two thirds of the daily excretion is accounted for by
urinary excretion, with the remaining one third being excreted into
the gut.
A number of studies have shown that alterations of SUA level are
linked to various human diseases, such as gout, hypertension,
cardiovascular disease, kidney disease, multiple sclerosis, Parkinson's
disease, Alzheimer's disease, and optic neuritis [3–12]. Therefore, it is
suggested that SUA level should be controlled within the normal
range between 120 and 380 μM, depending on gender [13]. However,
various pharmaceutical drugs are known to affect SUA levels [14]. For
example, some antihypertensive angiotensin II receptor blockers
(ARBs) inhibit uric acid transporters for reabsorption in kidney,
resulting in a decrease of SUA level. On the other hand, some ARBs,
which stimulate reabsorptive transporters or inhibit secretiontransporters, may cause an increase of SUA level [15–18]. But, to
date, it remains unclear how other drugs inﬂuence SUA level. To better
understand drug-induced alterations of SUA level, it is important to
clarify the uric acid handling mechanisms in human kidney. In
humans, excretion of uric acid into urine is a complex process, which
has been explained in terms of the so-called four-component model,
which includes glomerular ﬁltration, reabsorption, secretion and
post-secretory reabsorption [1]. Therefore, it is not easy to accurately
evaluate renal handling of uric acid in humans.
Animal models would be useful to examine uric acid excretion
mechanisms in detail, but species differences in renal handling of uric
acid are substantial [19]. For example, swine and rabbits excrete more
uric acid than is ﬁltered through the glomerulus, and uric acid is not
reabsorbed in avian kidney. Although the SUA level in rats is
maintained at a lower level by uricase, which metabolizes uric acid
to allantoin, uric acid is reabsorbed in kidney, as it is in humans.
Furthermore, studies using isolated BBMVs of kidney [20] indicate
that the rat renal transport system for uric acid is similar to that in
humans. Therefore, rats are considered to be a pertinent animal model
to evaluate the molecular and functional characteristics of the human
uric acid handling system.
Human urate transporter 1, URAT1 (SLC22A12), and mouse renal
speciﬁc transporter Rst (Slc22a12) have been identiﬁed as uric acid
transporters at the apical membrane of proximal tubular cells [21,22].
Since mutations of URAT1 in humans and deﬁciency of Rst in mice
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transporters are considered to play an important role in uric acid
handling in kidney. Although no functional studies have been
reported, the amino acid sequence of rat Urat1 (rUrat1) indicated
that this transporter might be the rat ortholog of human URAT1 [25].
Therefore, in the present study, we aimed to characterize rUrat1
function by examining the transport of uric acid in rUrat1-expressing
cells and BBMVs prepared from rat kidney. Furthermore, immunolo-
calization of rUrat1 expressed in kidneys was examined using an anti-
rat Urat1 polyclonal antibody raised in rabbits.
2. Materials and methods
2.1. Chemicals
[14C]Uric acid (1.96 TBq/mol) was purchased from Moravek
Biochemicals, Inc. (Brea, CA). All other reagents were purchased
from Kanto Chemicals (Tokyo, Japan), Sigma-Aldrich (St. Louis, MO),
and Wako Pure Chemical Industries Ltd. (Osaka, Japan), respectively.
2.2. Subcloning of rUrat1 (Slc22a12)
rUrat1 cDNA (pExpress-1/rUrat1) was purchased from Open
Biosystems (Huntsville, AL). The open reading frame of rUrat1 was
inserted into pcDNA3.1 (Invitrogen) at the EcoRI and NotI sites and
then transferred to pGEMHE [26] at the EcoRI and XbaI sites. For cRNA
synthesis, rUrat1 cDNA (pGEMHE/rUrat1) was digested with NheI.
The obtained cDNA sequence was veriﬁed (GenBank accession
no. BC103638).
2.3. Transport study using Xenopus laevis oocytes
Complementary RNA (cRNA) of rUrat1 was prepared by in vitro
transcription with T7 RNA polymerase in the presence of ribonuclease
inhibitor and an RNA cap analog using a mMESSAGE mMACHINE kit
(Ambion, Austin, TX). For transport experiments with rUrat1,
defolliculated oocytes were injected with 25 ng of rUrat1 cRNA or
the same volume of water and incubated in modiﬁed Barth's solution
(82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.4)
containing 50 μg/ml gentamycin at 18 °C for 3 days as reported
previously [16]. The oocytes were transferred to a 24-well plate and
preincubated in ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2,
1.8 mMCaCl2, and 5 mMHEPES, pH 7.4) at 25 °C for 60 min. To initiate
uptake of [14C]uric acid, the oocytes were incubated with uptake
buffer (96 mM Na gluconate, 2 mM K gluconate, 1 mM Mg gluconate,
1.8 mM Ca gluconate, and 5 mM HEPES, pH 7.4) containing 20 μM
[14C]uric acid at 25 °C for the designated time. In cis-inhibitory studies,
drugs tested were added simultaneously with [14C]uric acid. In the
trans-stimulation study, the oocytes were microinjected with 50 nl of
drug solution or water containing 1% dimethyl sulfoxide (DMSO).
Immediately after the microinjection (within approximately 2 min),
the oocyteswere transferred to uptake buffer containing [14C]uric acid
to initiate uptake. Uptake was terminated by washing the oocytes
three times with ice-cold uptake buffer. The oocytes were solubilized
with 5% sodium dodecyl sulfate solution.
2.4. Membrane preparation
Renal BBMVs were isolated from the kidney cortex of rats using a
calcium precipitation method according to the procedures reported
previously [27–29]. Experiments were approved by the Committee on
Care and Use of Laboratory Animals of Kanazawa University. Male
Sprague–Dawley rats (7–8 weeks old) were anesthetized with
diethylether. The kidneys were perfused with isotonic saline contain-
ing 0.5 mM phenylmethylsulfonyl ﬂuoride (PMSF) via the descending
aorta until cleared of blood, then removed and placed in ice-coldsaline containing 0.5 mM PMSF. After removal of the capsule, they
were sliced with a razor. The cortex was dissected from the medulla
and homogenized in ice-cold vesicle buffer-A solution containing
50 mMmannitol and 2 mM Tris/MES (pH 7.0) with a Waring blender
for 5 min at 18000 rpm. CaCl2 solution (1 M) was added to the
homogenate to give a ﬁnal concentration of 10 mM and the sus-
pensionwas stirred for 15 min at 4 °C, then centrifuged at 3000 × g for
15 min. The supernatant was further centrifuged at 43000 × g for
20 min. The resultant pellet was suspended, through a 25-gauge
needle, in ice-cold vesicle buffer-B (100 mM mannitol, 120 mM NaCl
and 10 mM HEPES/Tris (pH 7.4)) or buffer-C (60 mM mannitol,
125 mM Kgluconate, 10 mMHEPES/Tris (pH 7.4)) for trans-stimulation
study. The suspension was again centrifuged at 43000 × g for 20 mm,
and the resultantpelletwas resuspended inbuffer-B or buffer-C through
the same needle to give a protein concentration of 11.5±1.5 mg of
protein/ml.
The purity of the BBMVs was assessed in terms of the activity of
alkaline phosphatase, which is a marker enzyme for BBM. The activity
was enriched 16.5±2.9-fold (mean±S.E.M., n=6) with respect to
the initial homogenate. This level of enrichment of the marker
enzyme activity indicates that the isolated membrane fraction had
been adequately puriﬁed and was sufﬁciently rich in BBM.
2.5. Transport study using BBMVs
The uptake of [14C]uric acid by BBMVs was performed at 25 °C
using a rapid ﬁltration technique, as described previously [27]. After
preincubation of BBMVs at 25 °C for 1 min, the inﬂux of [14C]uric acid
was initiated by adding an aliquot of 90 μL of the uptake buffer
containing [14C]uric acid to 10 μL of membrane suspension for the
designated time. The uptake buffer was composed of 100 mM
mannitol, 120 mM Na gluconate and 10 mM HEPES/Tris (pH 7.4).
In the presence of Cl−, Na gluconate was replaced with NaCl. In
cis-inhibitory studies, tested drugs were added simultaneously with
[14C]uric acid. In the trans-stimulation study, BBMVswere preincubated
with 10 mM Na gluconate, Na L-lactate or Na pyrazine carboxylate,
115 mM K gluconate, 60 mMmannitol and 10 mM HEPES-Tris, pH 7.4.
Incubation was terminated by adding 1 ml of ice-cold stop solution
containing 140 mM mannitol and 120 mM Na gluconate, 0.1 mM
probenecid and 10 mM HEPES/Tris (pH 7.4) and immediately ﬁltered
through theMilliporeﬁlter (Millipore Ltd., Bedford,MA; 0.45 μm)under
vacuum. The ﬁlter was washed rapidly twice with 5 ml of ice-cold stop
solution.
2.6. Analytical method
For uptake studies, the radioactivity was measured using a liquid
scintillation counter (LSC-5100, Aloka, Tokyo). Uptakewas expressed as
the cell-to-medium ratio (μl per mg protein or per oocyte), obtained by
dividing the uptake amount by the concentration of substrate in the
uptake medium. In uptake studies using oocytes, results are shown as
mean±standard error obtained from10oocytes. Transporter-mediated
initial uptake rates were obtained after subtraction of the uptake by
water-injected oocytes from that by rUrat1 cRNA-injected oocytes. In
uptake studiesusingBBMVs, Cl− gradient-dependentuptake of uric acid
was determined by subtraction of the uptake in Cl−-containing buffer
from that inCl−-freebuffer. For the evaluationof thekinetic parameters,
the rateswereﬁtted to the followingEq. (1) bymeans of nonlinear least-
squares regression analysis using Kaleidagraph (Synergy Software,
Reading, PA).
v =
Vmax × s
Km + s
; ð1Þ
where v, s, Km, and Vmax are the initial uptake rate of substrate (pmol
per indicated time per mg protein or per oocyte), the substrate
Fig. 1. Uric acid transport by rUrat1. (a) Effect of pH and Cl− on uric acid uptake by rUrat1. Effects of extracellular pH and Cl− on the uptake of [14C]uric acid (20 μM) by water-
injected oocytes (open column) and Urat1-cRNA-injected oocytes (closed column) were examined at room temperature for 60 min. Cl− in the ND96 buffer was replaced with
gluconate. Each result represents themean±standard error (n=10), and * indicates a signiﬁcant difference from the uptake of [14C]uric acid by rUrat1-cRNA-injected oocytes under
Cl−-free conditions compared with that by rUrat1-cRNA-injected oocytes in the presence of Cl− by Student's t-test (pb0.05). (b) Time course of uric acid uptake by rUrat1. Uptakes
of [14C]uric acid (20 μM) by rUrat1-cRNA-injected oocytes (closed circles) and water-injected oocytes (open circles) were measured at room temperature and pH 7.4 over 120 min.
Each result represents themean±standard error from 8 to 10 oocytes, and * indicates a signiﬁcant difference from the uptake by water-injected oocytes by Student's t-test (pb0.05).
(c) Concentration dependence of uric acid uptake by rUrat1. Uptake of [14C]uric acid (20 μM) in the uptake buffer (Cl− removal buffer) by rUrat1-cRNA-injected oocytes and water-
injected oocytes were measured at room temperature and pH 7.4 for 60 min in the presence of 0.02–2 mM unlabeled uric acid. rUrat1-mediated uptake was determined
by subtracting the uptake by water-injected oocytes from that by Urat1-cRNA-injected oocytes. Each point represents the mean±standard error from 8 to 10 oocytes.
(d) Concentration dependence of inhibitory effect of benzbromarone on rUrat1. Uptake of [14C]uric acid (20 μM) by water-injected and rUrat1-cRNA-injected oocytes was measured
in the presence or absence (control) of benzbromarone (1–100 μM). rUrat1-mediated uptake was determined by subtracting the uptake by water-injected oocytes from that by
rUrat1-cRNA-injected oocytes, and the values obtained were divided by the control value in each assay. Each point represents the mean ± standard error from 8 to 10 oocytes. An
asterisk (*) indicates a signiﬁcant difference from the control by Student's t-test (pb0.05). (e) Trans-stimulatory effect on rUrat1-mediated uptake of uric acid. The uptake of [14C]uric
acid (20 μM) by water-injected or rUrat1-cRNA-injected oocytes was measured after preloading 50 nl of 100 mM PZA, 100 mM L-lactic acid, 100 mM nicotinate or the same volume
of water (Control, closed bar). An asterisk (*) indicates a signiﬁcant difference from the control by Student's t-test (pb0.05). Drugs were dissolved in water containing KOH, and
adjusted to pH 7.4 with MES.
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Menten constant (μmol/L), and the maximal uptake rate (pmol per
indicated time per mg protein or per oocyte), respectively. The
inhibitory effect was expressed as percentage of control, and the
inhibitor concentration giving 50% inhibition (IC50) was calculated by
application of the following equation (2),
% of control =
100 × IC50
IC50 + I
; ð2Þ
where I is the inhibitor concentration (μM).
For protein assay, cellular protein content wasmeasured according
to the method of Bradford [30] using a Bio-Rad protein assay kit (Bio-
Rad, Hercules, CA) with BSA as the standard.2.7. Immunohistochemistry
Male Wistar rats at 10–15 weeks of age were purchased from
Nippon SLC, Inc. (Hamamatsu, Japan). They were raised under
standard laboratory conditions with a 12-h light/12-h dark cycle and
free access to food and water. All subsequent animal experiments
approved by the Committee on Care and Use of Laboratory Animals
in Kanazawa University. The animals were anesthetized with an
intraperitoneal injection of sodium pentobarbital (50 mg/kg) and
sacriﬁced by bleeding from the right atrium, followed by transcardial
perfusion with cold physiological saline. To make tissue sections for
immunohistochemistry, the animals were ﬁxed by perfusion with
cold 4% paraformaldehyde in phosphate-buffered saline (pH 7.4),
and the kidneys were dissected out. They were further ﬁxed by
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Fig. 2. Cis-inhibitory effects of various endogenous and exogenous compounds on
rUrat1-mediated uptake of uric acid by rUrat1-expressing oocytes. Uptake of [14C]uric
acid (20 μM) by water-injected and rUrat1-cRNA-injected oocytes was measured in the
presence and absence (control, closed bar) of L-lactate, PAH, PZA, probenecid, losartan,
candesartan and telmisartan for 60 min. rUrat1-mediated uptake was determined by
subtracting the uptake in water-injected oocytes from that in rUrat1-cRNA-injected
oocytes, and the values obtained were divided by the control value in each assay.
Each point represents the mean±standard error from 8 to 10 oocytes. An asterisk (*)
indicates a signiﬁcant difference from the control by Student's t-test (pb0.05).
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graded alcohol series for 24 h, and embedded in parafﬁn. They were
then cut into 4-μm-thick sections utilizing a routine procedure. The
sections were mounted on silanized glass slides (DAKO, Glostrup,
Denmark).
Polyclonal rabbit anti-rUrat1 sera were raised against synthetic
peptides corresponding to 17-amino-acid sequences (321–337:
RSAMQEEPNGNQAGARL and 537–553: KVTHDIAGGSVLKSARL) of rat
Urat1. These peptides were conjugated to keyhole limpet hemocyanin
and used as antigens to immunize rabbits (Medical and Biological
Laboratories Co., Ltd., Nagoya, Japan). When the antibody titer had
increased above 62500, the whole blood was collected from each
rabbit and the sera were separated.
Immunohistochemistry was performed as previously described
[31]. Brieﬂy, the prepared tissue sections of rat kidneys were treated
with 0.3% H2O2 in methanol for 10 min to inhibit intrinsic peroxidase
activity and with 1% bovine serum albumin for 30 min to prevent
nonspeciﬁc antibody binding. Subsequently, the sections were
incubated overnight at 4 °C with anti-rUrat1 antibody (1:800) and
then washed with PBS. The sites of immunoreaction were visualized
by incubating the sections successively with biotinylated horse anti-
rabbit IgG antibody (Vector Laboratories, Burlingame, CA) for 1 h,
horseradish peroxidase-conjugated streptavidin (DAKO) for 1 h and
ImmPACT DAB Substrate (Vector Laboratories) for a few minutes. To
conﬁrm the speciﬁcity of the immunoreaction, the antibody was
preabsorbed with the peptide antigen used for the immunization
(10 μg peptide for 100 μl of diluted anti-rUrat1 antibody solution) for
1 h at room temperature prior to use.
3. Results
3.1. Uric acid uptake by rUrat1
To clarify the transport characteristics of rUrat1 proteins, uric
acid uptake by Xenopus oocytes expressing rUrat1 was examined.
When chloride was replaced with gluconate in the uptake buffer,
rUrat1-mediated uric acid uptake was signiﬁcantly increased by
about 5-fold compared to water-injected oocytes (Fig. 1a). rUrat1-
mediated uptake of uric acid was pH-dependent, showing slightly
lower activity at pH 6.0 than at pH 7.4 (Fig. 1a). In the following
studies, uric acid uptake by Xenopus oocytes expressing rUrat1 was
evaluated under Cl−-free conditions at pH 7.4. The uptake of uric acid
by rUrat1 was linearly increased with time over 120 min and was
signiﬁcantly greater than that by water-injected oocytes (Fig. 1b).
Uptake at 60 min was evaluated as a measure of initial uptake in
the subsequent studies. The concentration dependence of uric acid
uptake by rUrat1 was studied in the concentration range from 20 to
2000 μM (under this condition, solubility of uric acid is up to
2000 μM). All values are shown after subtraction of the uptake by
water-injected oocytes in Fig. 1c. The uptake was saturable, and
the Km and Vmax values of uric acid transport by rUrat1 were
1773±334 μM (mean and standard error) and 31.6±3.41 pmol/min/
oocyte, respectively. Uric acid uptake by rUrat1 expressing oocytes
was linearly increased over 2 mM in the presence of Cl− (data not
shown), suggesting that Km is larger than 2 mM. Accordingly, since
Km was 1.77 mM in the absence of Cl−, it was suggested that Cl−
lowers the afﬁnity of uric acid to rUrat1. Benzbromarone inhibited
rUrat1-mediated uptake of uric acid in a concentration-dependent
manner. The estimated IC50 value of benzbromaronewas11.9±1.72 μM
(Fig. 1d). Trans-stimulatory effects of lactate, pyrazinecarboxylic
acid (PZA) and nicotinate on rUrat1-mediated uptake of uric acid
were evaluated in oocytes injected with these compounds prior to
initiation of uric acid uptake. Each of the three compounds caused a
signiﬁcant increase of rUrat1-mediated uptake of uric acid (Fig. 1e).
Cis-inhibitory effects of several compounds on uric acid uptake by
rUrat1 were also examined. Lactate (10 mM, 26.7±1.38% of control),para-aminohippuric acid (PAH, 10 mM, 23.4±5.92%), PZA (10 mM,
39.2±5.34), probenecid (2 mM, 12.2±1.07%), and telmisartan (10 μM,
53.5±3.45%) signiﬁcantly reduced the rUrat1-mediated uric acid
uptake (Fig. 2), while losartan and candesartan at 10 nM and 10 μM,
respectively, had no effect.
3.2. Uric acid uptake by isolated BBMVs of rat kidney cortex
Transport properties of uric acid by isolated renal BBMVs from rat
kidney cortex were examined and compared with those of rUrat1-
expressing oocytes as described above. Uric acid uptake by renal
BBMVs was signiﬁcantly increased to 2.6-fold in Cl−-free buffer,
namely, in the presence of an outwardly directed Cl− gradient,
compared with chloride-containing buffer, namely in the absence
of a Cl− gradient. Uric acid uptake by BBMVs at pH 6.0 exhibited a
1.4-fold increase in comparison with that at pH 7.4 (Fig. 3a). Uric
acid uptake by BBMVs in the presence of an outwardly directed Cl−
gradient, using a Cl−-free uptake buffer, increased linearly until
30 sec, showing a transient overshoot uptake phenomenon, which
was not observed in the absence of a Cl− gradient. The uptake at
120 min in Cl−-free uptake buffer was lower than that at 120 s and
was comparable with that observed in the presence of Cl− in the
uptake buffer (Fig. 3b). Since uptake of uric acid by BBMVs was
enhanced by an outward Cl− gradient, the uptake rate was evaluated
by subtracting the value obtained in the presence of Cl− from that in
the absence of Cl− in the uptake buffer. The uptake of uric acid by
BBMVs exhibited saturation in a concentration range from 100 to
2000 μM. An Eadie-Hofstee plot indicated the involvement of a
single transport system with Km of 1129±242 μM and Vmax of
102.9±10.5 pmol/s/mg protein (Fig. 3c). The Cl−-susceptible uptake
of uric acid by BBMVs was inhibited by benzbromarone with an IC50
of 10.2±1.72 μM (Fig. 3d). Uric acid uptake by BBMVs was increased
by 54% and 65% by preincubation with 10 mM lactate and 10 mM
PZA, respectively (Fig. 3e), suggesting that both drugs trans-stimulate
uric acid transport.
3.3. Immunohistochemical localization of rUrat1 in rat kidney
To examine the intracellular localization of rUrat1, we performed
immunohistochemical analysis using parafﬁn-embedded sections of
Fig. 3. Uric acid transport by rat renal BBMVs. (a) Effect of pH and Cl− on uric acid uptake by BBMVs. Effects of extravesicular pH and Cl− on the uptake of [14C]uric acid (20 μM) by
BBMVs for 15 s at 25 °C. Cl− was replaced in the uptake buffer with gluconate. Each result represents the mean±standard error (n=3-4). * indicates signiﬁcant difference from
uptake of [14C14C]uric acid by BBMVs under control conditions by Student's t-test (pb0.05). (b) Time course of uric acid uptake by BBMVs. Uptake of [14C]uric acid (60 μM) by BBMVs
in the presence (open circles) or absence (closed circles) of Cl− was measured at 25 °C and pH 7.4 for designated time. Cl− was replaced in the uptake buffer with gluconate.
Each result represents the mean±S.E.M. from 3 to 4 points, and * indicates a signiﬁcant difference between the uptake of [14C]uric acid in the absence of Cl− and that in the presence
of Cl− by Student's t-test (pb0.05). (c) Concentration dependence of uric acid uptake by BBMVs. Uptake of [14C]uric acid (60 μM) by BBMVs in the presence and absence of Cl−was
measured at 25 °C and pH 7.4 for 15 s in the presence of 0.4 to 2 mM unlabeled uric acid. Cl− gradient-dependent uric acid uptake was determined by subtracting the uptake in the
presence of Cl− from that in the absence of Cl−. The inset shows an Eadie–Hofstee plot of the Cl− gradient-dependent uptake of uric acid. Each point represents the mean±standard
error from 3 to 4 points. (d) Concentration dependence of inhibitory effect of benzbromarone on uric acid uptake by BBMVs. Uptake of [14C]uric acid (60 μM) by rat BBMVs was
measured in the presence or absence (control) of benzbromarone (1–100 μM) for 15 s. Cl− gradient-dependent uric acid uptake was determined by subtracting the uptake in the
presence of the Cl− gradient from that in the absence of Cl−, and the values obtained were divided by the control value in each assay. Each point represents the mean ± standard
error from 3 to 4. An asterisk (*) indicates a signiﬁcant difference from the control by Student's t-test (pb0.05). (e) Trans-stimulatory effect on uptake of uric acid by BBMVs. Effects of
an outwardly directed L-lactic acid or PZA gradient on [14C]uric acid (60 μM) uptake in BBMVs were examined at 25 °C and pH 7.4. BBMVs was preincubated with 10 mM L-lactic acid
or 10 mM PZA at 25 °C and pH 7.4 for 90 min. 1 mM PZA or 1 mM L-lactic acid was added to uptake buffer-B as a control for L-lactic acid or PZA. Each point represents the mean
±standard error from 3 to 4 points. An asterisk (*) indicates a signiﬁcant difference from the control by Student's t-test (pb0.05).
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in the renal tubules and was not detected in the glomerulus (Fig. 4a).
Immunoreactivity for rUrat1 was not evenly distributed within renal
tubules, but was strong on the apical side of the proximal convoluted
tubules (Fig. 4c). Moderate to weak staining was seen in the distal
convoluted tubules, the loop of Henle and the collecting ducts (Fig. 4a
and d). When sections with preabsorbed antibody were examined, no
immunostaining was observed (Fig. 4b), suggesting that the immu-
noreactivity is speciﬁc to Urat1.
4. Discussion
rUrat1 cDNA exhibited 78.3% and 92.9% identity to hURAT1 and
mRst at the nucleotide level, respectively, and its mRNA is expressed
in kidney23-25. Therefore, rUrat1 is considered to play a role in uricacid handling in rat kidney. Nevertheless, it has remained unclear how
rUrat1 functions as a uric acid transporter in proximal tubular cells
and how it contributes to renal reabsorption of uric acid. The present
study establishes the functional expression and immunolocalization
of rUrat1 and compares rUrat1 activity with the activity of isolated
BBMVs from rat kidney and with that of hURAT1.
In rats, renal uric acid reabsorption is carrier-mediated, and the
transporter is suggested to be an anion exchanger, which has afﬁnity for
PAH [20,32]. Studies with rat renal BBMVs indicated that there are at
least two transport systems for uric acid; one is susceptible to an
outwardly directed hydroxyl ion gradient and has afﬁnity for bicarbon-
ate, and the other is susceptible to an outwardly directed Cl− gradient
and has afﬁnity for lactate [20,33]. Therefore, the hydroxyl ion- or Cl−-
sensitivity of rUrat1-mediated transport of uric acidwas ﬁrst examined.
Uric acid uptake by rUrat1 exhibited Cl− dependence, suggesting an
Fig. 4. Light microscopic immunohistochemistry showing the localization of rUrat1 in the adult rat kidney. Parafﬁn sections of 10–15 week kidney were immunostained with anti-
rUrat1 antibody (a, c, d) or anti-rUrat1 antibody preabsorbed with the peptide antigen for rUrat1. (a) rUrat1 immunoreactivity is present in the proximal (P) and distal (D) tubules,
whereas no reactivity is present in the glomerulus (G). (b) No reactivity is present in any region. (c) Strong immunoreactivity (arrowhead) is present in the apical portion of the
proximal convoluted tubules. (d) Moderate to weak immunoreactivity is present in the loop of Henle (H) and the collecting duct (C). Bars=100 μm (a, b) and 25 μm (c, d).
1446 M. Sato et al. / Biochimica et Biophysica Acta 1808 (2011) 1441–1447exchange transport of uric acidwith Cl−. In contrast, a negligible change
of uric acid uptake was observed in the presence of outwardly directed
OH- gradient (Fig. 1a). The Cl− gradient-susceptible uptakes of uric acid
by rUrat1 and BBMVswere saturablewith comparable Kmvalues (1773
and 1129 μM, respectively) (Figs. 1c and 3c). The IC50 values of
benzbromarone, which exhibits a uricosuric effect by inhibiting
hURAT1 in humans, for uric acid uptake by rUrat1 and rat renal
BBMVs were also comparable: 11.9 and 10.2 μM, respectively (Figs. 1d
and 3d). Furthermore, uptake of uric acid by rUrat1 and Cl− gradient-
susceptible uptake of uric acid by BBMVs were trans-stimulated by
preloading of lactate and PZA (Figs. 1e and 3e). In addition, our
preliminary comparison of the inhibitory effects of salicylate, losartan
and telmisartan on the uptake of uric acid between rUrat1 and BBMVs
were comparable, showing IC50 of salicylate, losartan and telmisartan
were 352, 151 and 11 μM in rUrat1, respectively, and 217, 28 and 10 μM
by BBMVs, respectively. These results suggest that the functional
characteristics of rUrat1 are essentially the same as those of Cl−
gradient-susceptible uric acid uptake at the apical membrane in rat
kidney. We conﬁrmed functional identiﬁcation of rUrat1 on Cl−
gradient-susceptible uptake of uric acid by rat renal BBMVs, although
hURAT1 and mRst don't.
Micropuncture studies indicated that approximately 65% of the
ﬁltered load of uric acid is reabsorbed in the proximal convoluted
tubule, and there are additional reabsorptive sites between the late
proximal tubule and the early distal tubule in rats [20]. Free ﬂow
micropuncture studies also established that distal nephron segments
of rat have extremely low permeability [20]. Our immunohistochem-
ical results demonstrated that rUrat1 is mainly immunolocalized at
the apical membrane in proximal tubular epithelial cells and is
expressed to a lesser extent in distal convoluted tubules, the loop of
Henle and the collecting ducts (Fig. 4). These observations supported
the hypothesis that rUrat1 functions to reabsorb uric acid in rat
kidney.Uptake of uric acid by rUrat1 was Cl−-dependent but was only
slightly pH-dependent (Fig. 1a), like that by hURAT1 [21]. The Kmvalue
of uric acid uptake by rUrat1 (1773 μM) is greater than that by hURAT1
(371±28 μM) [21] and is comparable to that by mRst (1213 μM) [22].
The IC50 value of benzbromarone (12 μM) is also higher than that for
hURAT1 (around 100 nM) [21] and is comparable to that in the case of
mRst [22]. Although the Ki values of losartan and telmisartan for
hURAT1 are 7.7 nMand 18.2 nM, respectively, the estimated IC50 values
of these drugs on rUrat1 are higher than 10 μM. On the other hand, the
inhibitory effects of other endogenous and exogenous compounds,
including lactate, PAH, and PZA, on rUrat1-mediated uptake were
similar to those on hURAT1 and mRst [21,22] (Fig. 2). These
observations indicate that the transport characteristics of rUrat1 are
similar to those of mRst. Although there are differences in the afﬁnities
of some compounds, such as benzbromarone and ARBs, between rUrat1
and hURAT1, it is thought that the exchange transport properties of
rUrat1, such as Cl− dependence and trans-stimulation by lactate and
PZA, are essentially the same as those of hURAT1. The similarities of the
signiﬁcance of URAT1 for the reabsorption of uric acid between humans
and rats is useful to predict the in vivo effect of drugs on human SUA
level from rat studies. However, we should be careful about the
difference of afﬁnity of drugs between human and rat URAT1 for the
prediction of the in vivo change in SUA level in humans by each drug.
Since missense mutations of hURAT1 gene in humans cause an
increase in urinary excretion of uric acid and the uricosuric agent
benzbromarone inhibits hURAT1, hURAT1 is thought to be an
essential transporter for uric acid reabsorption in humans [21,23].
Although mRst was reported to mediate uric acid efﬂux in in vitro
experiments [34], mRst likely plays a role in uric acid reabsorption in
mouse, because mRst-deﬁcient mice show increased urinary uric acid
excretion [24]. Since rUrat1 activity is accelerated by preloading
of lactate, which is an anion imported into cytoplasm by lactate
transporters, such as SMCT1 [35] and SMCT2 [36], and produced
1447M. Sato et al. / Biochimica et Biophysica Acta 1808 (2011) 1441–1447by cellular metabolism [37], rUrat1-mediated uric acid reabsorption
may be affected by the availability of intracellular lactate in rat kidney.
In conclusion, our results indicate that rUrat1 plays a role in uric
acid transport at the apical membrane of proximal tubular epithelial
cells. Furthermore, it appears that rUrat1 mediates reabsorption of
uric acid in a similar manner to hURAT1. Therefore, it should be
possible to extrapolate ﬁndings obtained with rUrat1 to uncover the
mechanisms in humans of the alterations of SUA level and urinary
excretion of uric acid by drugs and other agents.
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